Related Experiment Video
Updated: Mar 22, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
MYBPC3 hypertrophic cardiomyopathy can be detected by using advanced ECG in children and young adults
E Fernlund1, P Liuba2, J Carlson3
1Department of Pediatric Cardiology, Pediatric Heart Center, Skane University Hospital and Lund University; Department of Pediatrics, Linkoping University Hospital, Linkoping University, Sweden.
Insights
An advanced 12-lead ECG score significantly improves detection of hypertrophic cardiomyopathy (HCM) in young individuals. This new method shows greater sensitivity and specificity than conventional ECG for identifying MYBPC3-HCM.
Area of Science:
- Cardiology
- Genetics
- Medical Diagnostics
Background:
- Conventional ECG has limitations in diagnosing hypertrophic cardiomyopathy (HCM), especially in children and athletes, with up to 25% of adults and higher percentages of children with HCM showing no distinct abnormalities.
- A novel 5-minute resting advanced 12-lead ECG (A-ECG) score has demonstrated superiority over conventional ECG criteria in identifying adult HCM.
Purpose of the Study:
- To evaluate the sensitivity and specificity of the A-ECG score in detecting echocardiographic HCM associated with the MYBPC3 genetic mutation in children and young adults.
- To assess the A-ECG score's ability to differentiate individuals with MYBPC3 HCM from healthy controls and young athletes.
Main Methods:
- A-ECG and conventional ECGs were obtained from 15 young patients (0-30 years) with MYBPC3 mutation and phenotypic HCM.
- ECG results were compared to those of 198 healthy children and young adults (1 month-30 years) and 36 young endurance-trained athletes.
Main Results:
- The A-ECG score increased sensitivity for detecting MYBPC3 HCM from 46% to 87% compared to conventional ECG criteria (p<0.05).
- The A-ECG score demonstrated superior specificity in healthy controls (94% vs. 87%, p<0.01) and particularly in young athletes (100% vs. 69%, p<0.001).
Conclusions:
- A 2-parameter 12-lead A-ECG score is significantly more sensitive and specific than conventional ECG criteria for detecting MYBPC3-HCM in children and young adults.
- The A-ECG score effectively distinguishes patients with MYBPC3 HCM from healthy individuals, including endurance-trained athletes.
Introduction:
The conventional ECG is commonly used to screen for hypertrophic cardiomyopathy (HCM), but up to 25% of adults and possibly larger percentages of children with HCM have no distinctive abnormalities on the conventional ECG, whereas 5 to 15% of healthy young athletes do. Recently, a 5-min resting advanced 12-lead ECG test ("A-ECG score") showed superiority to pooled criteria from the strictly conventional ECG in correctly identifying adult HCM. The purpose of this study was to evaluate whether in children and young adults, A-ECG scoring could detect echocardiographic HCM associated with the MYBPC3 genetic mutation with greater sensitivity than conventional ECG criteria and distinguish healthy young controls and athletes from persons with MYBPC3 HCM with greater specificity.
Methods:
Five-minute 12-lead ECGs were obtained from 15 young patients (mean age 13.2years, range 0-30years) with MYBPC3 mutation and phenotypic HCM. The conventional and A-ECG results of these patients were compared to those of 198 healthy children and young adults (mean age 13.2, range 1month-30years) with unremarkable echocardiograms, and to those of 36 young endurance-trained athletes, 20 of whom had athletic (physiologic) left ventricular hypertrophy.
Results:
Compared with commonly used, age-specific pooled criteria from the conventional ECG, a retrospectively generated A-ECG score incorporating results from just 2 derived vectorcardiographic parameters (spatial QRS-T angle and the change in the vectorcardiographic QRS azimuth angle from the second to the third eighth of the QRS interval) increased the sensitivity of ECG for identifying MYBPC3 HCM from 46% to 87% (p<0.05). Use of the same score also demonstrated superior specificity in a set of 198 healthy controls (94% vs. 87% for conventional ECG criteria; p<0.01) including in a subset of 36 healthy, young endurance-trained athletes (100% vs. 69% for conventional ECG criteria, p<0.001).
Conclusions:
In children and young adults, a 2-parameter 12-lead A-ECG score is retrospectively significantly more sensitive and specific than pooled, age-specific conventional ECG criteria for detecting MYBPC3-HCM and in distinguishing such patients from healthy controls, including endurance-trained athletes.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Mitral Stenosis II: Clinical features and Diagnostic Tests
Hypertension III: Clinical Manifestations and Diagnostic Studies

